The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression

B-cell receptors, multiple receptor tyrosine kinases, and downstream effectors are constitutively active in chronic lymphocytic leukemia (CLL) B cells. Activation of these pathways results in resistance to apoptosis and enhanced survival of the leukemic cells. Idelalisib is a highly selective inhibi...

Full description

Bibliographic Details
Main Authors: Lisa Rohrbacher, Bettina Brauchle, Ana Ogrinc Wagner, Michael von Bergwelt-Baildon, Veit L. Bücklein, Marion Subklewe
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Immunology
Subjects:
cancer immunotherapy
chronic lymphocytic leukemia
idelalisib
immune effector cells
PI3K inhibition
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.608625/full

Similar Items

Similar Items